Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Neurology

• Publication date

  2008-10-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-008-0061-1PMID 19005625
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial

  2008cited by this paper
• Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

  2008cited by this paper
• Melanoma complicating treatment with natalizumab for multiple sclerosis.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies.

  2007cited by this paper
• Lack of association between antimyelin antibodies and progression to multiple sclerosis.

  2007cited by this paper
• Multiple Endocrine Neoplasia Syndromes

  2007cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.

  2007cited by this paper
• Lack of association between antimyelin antibodies and progression to multiple sclerosis.

  2007cited by this paper
• Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica

  2007cited by this paper
• A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

  2007cited by this paper
• Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

  2007cited by this paper
• Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

  2007cited by this paper
• Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

  2007cited by this paper
• Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

  2007cited by this paper
• Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

  2007cited by this paper
• Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis

  2007cited by this paper
• Daclizumab phase II trial in relapsing and remitting multiple sclerosis

  2007cited by this paper
• Guidelines on use of anti‐IFN‐B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐B antibodies in multiple sclerosis

  2007influential reference
• Left insular stroke is associated with adverse cardiac outcome

  2006cited by this paper
• Selective treatment of multiple sclerosis.

  2006cited by this paper
• Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre.

  2006cited by this paper
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  2006cited by this paper
• Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis

  2006cited by this paper
• IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

  2006cited by this paper
• EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis

  2006cited by this paper
• Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

  2006cited by this paper
• A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

  2006cited by this paper
• Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis

  2006cited by this paper
• Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

  2006cited by this paper
• Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis

  2006cited by this paper
• Effect of mitoxantrone on MRI in progressive MS : Results of the MIMS trial. Author's reply

  2006cited by this paper
• Mycophenolate mofetil in dermatomyositis: Is it safe?

  2006cited by this paper
• Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

  2006cited by this paper
• Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.

  2006cited by this paper
• Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG

  2006cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

  2006cited by this paper
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  2006cited by this paper
• Human demyelinating disease and the polyomavirus JCV

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• MS treatment: new perspectives.

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Oral fingolimod (FTY720) for relapsing multiple sclerosis.

  2006cited by this paper
• Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

  2006cited by this paper
• Symptomatic Treatment of Multiple Sclerosis

  2006cited by this paper
• Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

  2006cited by this paper
• A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Authors' reply

  2006cited by this paper
• Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects

  2005cited by this paper
• Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.

  2005cited by this paper
• Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event

  2005cited by this paper
• Neutralizing antibodies and efficacy of interferon β-1a

  2005cited by this paper
• Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis

  2005influential reference
• Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

  2005influential reference
• Cladribine for multiple sclerosis: review and current status

  2005cited by this paper
• The reproductive effects of beta interferon therapy in pregnancy

  2005cited by this paper
• Natalizumab and PML

  2005cited by this paper
• The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

  2005cited by this paper
• A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta

  2005cited by this paper
• Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®)

  2005cited by this paper
• The window of therapeutic opportunity in multiple sclerosis

  2005cited by this paper
• Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

  2005cited by this paper
• Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis

  2005cited by this paper
• Interferon β-1a in MS

  2005cited by this paper
• Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a

  2005cited by this paper
• Intravenous Immunoglobulins in MS.

  2005cited by this paper
• Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

  2005cited by this paper
• Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis

  2005cited by this paper
• Mycophenolate mofetil and neurological diseases

  2005cited by this paper
• Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

  2005cited by this paper
• The efficacy of glatiramer acetate in β‐interferon‐intolerant MS patients

  2005cited by this paper
• Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study

  2005cited by this paper
• A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

  2005cited by this paper
• Effect of mitoxantrone on MRI in progressive MS

  2005cited by this paper
• Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.

  2005cited by this paper
• Multiple sclerosis diagnostic criteria: three years later

  2005cited by this paper
• Anti-adhesion therapies.

  2005cited by this paper
• Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

  2005cited by this paper
• Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis

  2005cited by this paper
• Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort

  2005cited by this paper
• Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

  2005cited by this paper
• Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study

  2004cited by this paper
• Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

  2004cited by this paper
• Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

  2004cited by this paper
• Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody

  2004cited by this paper
• Mitoxantrone

  2004influential reference
• Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

  2004cited by this paper
• Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

  2004cited by this paper
• Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

  2004cited by this paper
• Plasma exchange for severe optic neuritis

  2004cited by this paper
• Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects

  2004cited by this paper
• Randomized multicenter trial of natalizumab in acute MS relapses

  2004cited by this paper
• Mycophenolate Mofetil in Multiple Sclerosis

  2004cited by this paper

• Exosome‐Based Therapeutics: A Natural Solution to Overcoming the Blood–Brain Barrier in Neurodegenerative Diseases

  2025cites this paper
• Beneficial therapeutic plasma exchange response in the treatment of severe relapses in patients with multiple sclerosis

  2024cites this paper
• Live-attenuated vaccines for multiple sclerosis patients living in regions with endemic infections: A complex decision

  2024cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

  2023cites this paper
• The role and therapeutic applications of exosomes in multiple sclerosis disease

  2022cites this paper
• A Pivotal Role of Nrf2 in Neurodegenerative Disorders: A New Way for Therapeutic Strategies

  2022cites this paper
• Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis

  2021cites this paper
• Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

  2021cites this paper
• Decision-making about corticosteroids in relapses of multiple sclerosis - development of a questionnaire based on the theory of planned behaviour.

  2021cites this paper
• Adherencia al tratamiento con inmunomoduladores inyectables en pacientes con esclerosis múltiple y trastorno cognitivo

  2021cites this paper
• Adherence to treatment with injectable immunomodulators in patients with multiple sclerosis and cognitive disorder

  2021cites this paper
• Immunmediierte Erkrankungen des Nervensystems

  2020cites this paper
• Rapamycin Alleviates the Symptoms of Multiple Sclerosis in Experimental Autoimmune Encephalomyelitis (EAE) Through Mediating the TAM-TLRs-SOCS Pathway

  2020cites this paper
• Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis

  2020cites this paper
• Immunadsorption: Eine Übersicht zum klinischen Einsatz

  2020cites this paper
• Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis

  2020cites this paper
• Immune System Sex Differences May Bridge the Gap Between Sex and Gender in Fibromyalgia

  2020cites this paper
• Plasmapheresis

  2020cites this paper
• Immunadsorption und therapeutischer Plasmaaustausch

  2019cites this paper
• Schwanger und krank — was ist zu tun?

  2019cites this paper
• Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study.

  2019cites this paper
• Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis

  2019cites this paper
• Immunoadsorption or plasma exchange in steroid‐refractory multiple sclerosis and neuromyelitis optica

  2019cites this paper
• Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review

  2019cites this paper
• Significance of multiple sclerosis early treatment

  2019cites this paper
• Health locus of control and mental health in patients with multiple sclerosis: Mediating effect of coping strategies.

  2019cites this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

  2019cites this paper
• Immunadsorption und therapeutischer Plasmaaustausch Welche Indikationen gibt es in Nephrologie und Neurologie?

  2019cites this paper
• Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies.

  2019cites this paper
• Význam včasnej liečby sclerosis multiplex

  2019cites this paper
• Hydrogen-Rich Saline Ameliorates Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice Via the Nrf2-ARE Signaling Pathway

  2018cites this paper
• Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis

  2018cites this paper
• Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy

  2018cites this paper
• Distinct Cytokine and Chemokine Expression in Plasma and Calpeptin-Treated PBMCs of a Relapsing-Remitting Multiple Sclerosis Patient: A Case Report

  2018cites this paper
• Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach

  2018cites this paper
• Management of multiple sclerosis patients in central European countries: current needs and potential solutions

  2018cites this paper
• Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica

  2018cites this paper
• Dendrimers: Breaking the paradigm of current musculoskeletal autoimmune therapies

  2018cites this paper
• Consenso Mexicano para la prescripción de inmunoglobulina G como tratamiento de reemplazo e inmunomodulación

  2018cites this paper
• Quality of life of people with multiple sclerosis – review of the literature

  2018cites this paper
• Alemtuzumab CARE-MS I 5-year follow-up

  2017cites this paper
• Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

  2017cites this paper
• Symptomatic treatment in multiple sclerosis—interim analysis of a nationwide registry

  2017cites this paper
• Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients.

  2017cites this paper
• Pattern Recognition of the Multiple Sclerosis Syndrome

  2017cites this paper
• Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes

  2017influential citation
• Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2—Surveillance for Treatment Complications and Disease Progression

  2017cites this paper
• Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

  2017cites this paper
• Safety and efficacy response to interferon beta‐1a therapy in Japanese patients with multiple sclerosis: Interim results of a postmarketing surveillance study

  2016cites this paper
• SclerosisDiagnosis and Follow-Up of Multiple MRI Protocol and Clinical Guidelines for the Standardized of MS Centers Task Force for a Revised Recommendations of the Consortium

  2016cites this paper
• The future of multiple sclerosis treatments

  2016cites this paper
• The future of MS Treatments

  2016cites this paper
• Aktuelles aus Diagnostik und Therapie

  2016cites this paper
• Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.

  2016cites this paper
• Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

  2016cites this paper
• Disease-modifying therapies and infectious risks in multiple sclerosis

  2016cites this paper
• Vestibular and ocular motor function prior to and after therapeutic apheresis with small plasmafilter in multiple sclerosis

  2016cites this paper
• Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series.

  2016cites this paper
• Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

  2016cites this paper
• Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients

  2016cites this paper
• Human immunoglobulin G suppresses the production of matrix metalloproteinase‐9 in peripheral blood mononuclear cells of patients with multiple sclerosis

  2015cites this paper
• Kapitel 17 – Symptomatische Therapie

  2015cites this paper
• Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

  2015cites this paper
• Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β

  2015cites this paper
• Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson’s disease

  2015cites this paper
• Infection Risk in Patients on Multiple Sclerosis Therapeutics

  2015cites this paper
• Eligibility Criteria to Natalizumab Therapy in Patients with RelapsingremittingMultiple Sclerosis: A Real-life Study in an Italian Population-basedCohort

  2015cites this paper
• [Criteria of ineffectiveness of treatment with first-line therapy: how to use MRI results in decision making?].

  2015cites this paper
• Optimizing therapy early in multiple sclerosis: An evidence-based view.

  2015cites this paper
• Apheresis in treatment of acute inflammatory demyelinating disorders.

  2015cites this paper
• Immuntherapien und infektiologische Probleme bei Multipler Sklerose

  2015cites this paper
• [Relevance of Magnet Resonance Tomography in the Diagnosis and Assessment of Course of Disease in Patients with Multiple Sclerosis].

  2015cites this paper
• Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial

  2015cites this paper
• MS Lesions Are Better Detected with 3D T1 Gradient-Echo Than with 2D T1 Spin-Echo Gadolinium-Enhanced Imaging at 3T

  2015cites this paper
• Magnetresonanztomografie bei Patienten mit Multipler Sklerose: Relevanz in der Diagnose und Verlaufsbeurteilung

  2015cites this paper
• [Intravenous immunoglobulins: perspectives in multiple sclerosis (a literature review with own results)].

  2015cites this paper
• Optimizing treatment success in multiple sclerosis

  2015cites this paper
• A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis.

  2015cites this paper
• Come modificare la terapia nel paziente experienced

  2015cites this paper
• Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients

  2015cites this paper
• Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

  2015influential citation
• Effect of Methylprednisolone on Mammalian Neuronal Networks In Vitro

  2014cites this paper
• The Potential of Human Amnion Epithelial Cells as an Immunomodulatory and Neuroregenerative Treatment for Multiple Sclerosis

  2014cites this paper
• [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].

  2014cites this paper
• Therapeutic Plasma Exchange in Glucocorticosteroid‐Unresponsive Patients With Clinically Isolated Syndrome

  2014influential citation
• Propozycje modyfikacji programów lekowych dotyczących stwardnienia rozsianego. Stanowisko Grupy Ekspertów Polskiego Towarzystwa Neurologicznego

  2014cites this paper
• The current role of mitoxantrone in the treatment of multiple sclerosis

  2014cites this paper
• Youth and environmental enrichment generate serum exosomes containing miR‐219 that promote CNS myelination

  2014cites this paper
• What are exosomes and how can they be used in multiple sclerosis therapy?

  2014cites this paper
• Multiple sclerosis treatment and infectious issues: update 2013

  2014cites this paper
• Exercise therapy and multiple sclerosis: a systematic review

  2014cites this paper
• Fingoli mod v klinickĂŠ praxi - kazuistiky

  2014cites this paper
• Ephrine und Eph-Rezeptoren in der Pathogenese der Multiplen Sklerose und der Experimentellen Autoimmunen Enzephalomyelitis

  2014cites this paper
• Socio-economic aspects of the testing for antibodies in MS-patients under interferon therapy in Austria: a cost of illness study.

  2014cites this paper
• Mitoxantrone – an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis

  2014cites this paper
• Clinical, laboratory and imaging features of patients with relapsing remitting multiple sclerosis or clinically isolated syndrome at the time of decision to start disease modifying treatment

  2014influential citation
• Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

  2014cites this paper
• Multiple sclerosis and pregnancy; What a neurologist may be asked for?

  2014cites this paper
• Relapsing MS: Disease Staging and Therapeutic Algorithms

  2014cites this paper
• Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients

  2013influential citation